PropThink: ENDP Guides 2013 Below Street, Stock Cheap, Buy Weakness For A Bounce

[ACN Newswire] – By David MoskowitzEndo Pharmaceuticals (NASDAQ:ENDP) is hosting its analyst day today in NY, and despite guiding for lower 2013 revenues and EPS compared to Wall Street Consensus estimates, we believe … more

View todays social media effects on ENDP

View the latest stocks trending across Twitter. Click to view dashboard